Supporting strategic fundamental research in life sciences through carefully selected projects from universities in the Wallonia-Brussels Federation, with a view to transforming their discoveries into industrial applications.
David Alsteens (WELBIO – UCLouvain) et son équipe démontrent l’interaction entre les acides sialiques à la surface cellulaire et la protéine spike, et développent des molécules qui permettent de bloquer cette interaction in vitro.
Le Prix Vicomtesse Valine de Spoelberch 2022 de la Fondation Médicale Reine Elisabeth a été attribué à Guido Bommer (WELBIO – UCLouvain) lors d’une cérémonie en présence de S.A.R. la Princesse Astrid.
Les résultats de l'appel 2021 sont connus: plus de 13 millions € pour 23 nouveaux programmes WELBIO !
WELBIO supports excellence in strategic basic research in life sciences. This mission is carried out within the framework of the « Fonds de la Recherche Fondamentale Stratégique » (FRS-FNRS).
WELBIO regularly meets with WELBIO Investigators and TTO representatives to discuss scientific advances, identify intellectual property and facilitate the translation of discoveries into biotechnology applications.
The Bridge Fund is a funding instrument intended for WELBIO Investigators and designed to bridge the gap between early-stage intellectual property and the development of a competitive package for the next technology transfer step.
WELBIO has gradually built up valorization opportunities that are taking many forms including projects supported by Biowin and SPW Research, licensing agreements, industry partnerships, and spin-off creation.
